0001193125-21-190091.txt : 20210614 0001193125-21-190091.hdr.sgml : 20210614 20210614163135 ACCESSION NUMBER: 0001193125-21-190091 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20210610 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20210614 DATE AS OF CHANGE: 20210614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERRIMACK PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001274792 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35409 FILM NUMBER: 211014967 BUSINESS ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-441-1000 MAIL ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 8-K 1 d158595d8k.htm 8-K 8-K
MERRIMACK PHARMACEUTICALS INC false 0001274792 0001274792 2021-06-10 2021-06-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 14, 2021 (June 10, 2021)

 

 

Merrimack Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-35409   04-3210530
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

One Broadway, 14th Floor
Cambridge, MA 02142
(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (617) 441-1000

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common stock, $0.01 par value   MACK   Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

At the 2021 Annual Meeting of Stockholders of Merrimack Pharmaceuticals, Inc. (the “Company”) held exclusively through a virtual format on June 10, 2021, the Company’s stockholders voted as follows:

1. The stockholders elected the nominees listed below to the Company’s board of directors (the “Board”), each for a one year term ending at the Company’s 2021 annual meeting of stockholders.

 

Nominees

   For      Against      Abstain      Broker Non-Votes  

Gary L. Crocker

     5,660,685        993,233        12,516        2,545,677  

Eric D. Andersen

     5,652,662        1,000,200        13,572        2,545,677  

Noah G. Levy

     5,608,690        994,152        63,592        2,545,677  

Ulrik B. Nielsen, Ph.D.

     5,356,445        1,246,257        63,732        2,545,677  

Russell T. Ray

     5,634,287        967,925        64,222        2,545,677  

2. The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.

 

     Votes  

For:

     5,522,300  

Against:

     1,110,176  

Abstain:

     33,958  

Broker Non-Votes

     2,545,677  

3. The stockholders approved, on a non-binding advisory basis, the one-year frequency of “say-on-pay” votes.

 

Frequency

   Votes  

1 year:

     6,113,951  

2 year:

     27,083  

3 year:

     517,418  

Abstain

     7,982  

Broker Non-Votes

     2,545,677  


4.The stockholders ratified the selection of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.

 

     Votes  

For:

     9,184,891  

Against:

     22,419  

Abstain:

     4,801  

5. The stockholders approved the adoption of the Company’s 2021 Incentive Award Plan as set forth on Annex A in the Company’s Definitive Proxy Statement for the 2021 Annual Meeting of Stockholders.

 

     Votes  

For:

     5,428,711  

Against:

     1,219,106  

Abstain:

     18,617  

Broker Non-Votes

     2,545,677  


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

                                     MERRIMACK PHARMACEUTICALS, INC.
Date: June 14, 2021     By:  

  /s/ Gary L. Crocker

        Gary L. Crocker
        President
EX-101.SCH 2 mack-20210610.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 mack-20210610_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 mack-20210610_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 d158595d8k_htm.xml IDEA: XBRL DOCUMENT 0001274792 2021-06-10 2021-06-10 MERRIMACK PHARMACEUTICALS INC false 0001274792 8-K 2021-06-10 DE 001-35409 04-3210530 One Broadway 14th Floor Cambridge MA 02142 (617) 441-1000 false false false false Common stock, $0.01 par value MACK NASDAQ false XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information
Jun. 10, 2021
Cover [Abstract]  
Entity Registrant Name MERRIMACK PHARMACEUTICALS INC
Amendment Flag false
Entity Central Index Key 0001274792
Document Type 8-K
Document Period End Date Jun. 10, 2021
Entity Incorporation State Country Code DE
Entity File Number 001-35409
Entity Tax Identification Number 04-3210530
Entity Address, Address Line One One Broadway
Entity Address, Address Line Two 14th Floor
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code (617)
Local Phone Number 441-1000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, $0.01 par value
Trading Symbol MACK
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d158595d8k.htm mack-20210610.xsd mack-20210610_lab.xml mack-20210610_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d158595d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d158595d8k.htm" ] }, "labelLink": { "local": [ "mack-20210610_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "mack-20210610_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "mack-20210610.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mack", "nsuri": "http://www.merrimackpharma.com/20210610", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d158595d8k.htm", "contextRef": "duration_2021-06-10_to_2021-06-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d158595d8k.htm", "contextRef": "duration_2021-06-10_to_2021-06-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.merrimackpharma.com//20210610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001193125-21-190091-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-190091-xbrl.zip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end